Real-world profile and clinical impact of central nervous system adverse events in patients with ALK-positive NSCLC treated with first-line lorlatinib in Japan: The first interim analysis from the ROYAL study

International Journal of Lung Cancer · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles